Last Update

This profile was last updated on 10/31/2017 and contains contributions from the  ZoomInfo Community.

is this you? Claim your profile.

Wrong David Kleinman?

David M. Kleinman

Chief Medical Officer

ONL Therapeutics Inc

HQ Phone:  (734) 272-4688

Email: d***@***.com

Get Zoominfo Grow
Community Edition

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    the Plugin
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check Your Inbox to
    Sign Up for ZoomInfo Community Edition

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

ONL Therapeutics Inc

1600 HURON PKWY

Ann Arbor, Michigan, 48109

United States

Company Description

ONL Therapeutics (ONL) is a biopharmaceutical company committed to protecting and improving the vision of patients with a range of retinal diseases and conditions, including retinal detachment and both the wet and dry forms of age-related macular degeneration ...more

Find other employees at this company (5)

Background Information

Employment History

Chief of Ophthalmology

DENVER HEALTH PARAMEDIC DIVISION


Associate Professor of Ophthalmology (Part Time)

Flaum Eye Institute at the University of Rochester


Chief Executive Officer

Eyeon Particle Sciences LLC


Staff Ophthalmologist

ORBIS International


Affiliations

start-up company Eyeon Therapeutics Inc.

Founder


Education

BA

Brown University


Dean's Scholar

Simon School of Business


M.B.A.


M.D.

The University of Rochester Eye Institute


M.D.

University of Rochester Eye Institute - Donald Grover


M.D. with honors

University of Colorado School of Medicine


MBA

Simon School of Business


Web References(39 Total References)


Management - ONL Therapeutics

David M. Kleinman, M.D., M.B.A., Chief Medical Officer
Dr. Kleinman is a board-certified ophthalmologist with fellowship training in vitreoretinal surgery and more than ten years experience in venture creation and ophthalmic drug and device development. He currently serves as a part-time associated professor ophthalmology at the Flaum Eye Institute at the University of Rochester, where he specializes in the medical and surgical care of patients with retinal disease. David is the former chief of ophthalmology at Denver Health Medical Center, where he also served as an assistant professor of ophthalmology at the Rocky Mountain Lions Eye Institute. In 2003, he helped found MacuSight, a venture capital backed retinal drug development company, where served as consulting medical director. In his role with MacuSight, David assisted in guiding the company through Series A financing, pre-clinical studies, initial investigational new drug (IND) submission, and Phase I/II clinical development. MacuSight's assets were acquired by Santen in 2010. He holds a bachelor's degree from Brown University, an MBA from the Simon School of Business, and an M.D. with honors from the University of Colorado School of Medicine.


Targeting Fas in Retinal Disease

David M. Kleinman, MD, MBA, Rocherster, N.Y., and David N. Zacks, MD, PhD, Ann Arbor, Mich.
Dr. Kleinman is a part-time associate professor of ophthalmology at the Flaum Eye Institute at the University of Rochester where he specializes in the medical and surgical care of patients with retinal disease. He has spent more than 10 years working in retinal pharmaceutical development and currently serves as the chief medical officer at ONL Therapeutics Inc.


Management – ONL Therapeutics

David M. Kleinman, M.D., M.B.A., Chief Medical Officer
Dr. Kleinman is a board-certified ophthalmologist with fellowship training in vitreoretinal surgery and more than ten years experience in venture creation and ophthalmic drug and device development. He currently serves as a part-time associated professor ophthalmology at the Flaum Eye Institute at the University of Rochester, where he specializes in the medical and surgical care of patients with retinal disease. David is the former chief of ophthalmology at Denver Health Medical Center, where he also served as an assistant professor of ophthalmology at the Rocky Mountain Lions Eye Institute. In 2003, he helped found MacuSight, a venture capital backed retinal drug development company, where served as consulting medical director. In his role with MacuSight, David assisted in guiding the company through Series A financing, pre-clinical studies, initial investigational new drug (IND) submission, and Phase I/II clinical development. MacuSight's assets were acquired by Santen in 2010. He holds a bachelor's degree from Brown University, an MBA from the Simon School of Business, and an M.D. with honors from the University of Colorado School of Medicine.


http://www.reviewofophthalmology.com/content/t/ocular_disease/c/56761/

David M. Kleinman, MD, MBA, Rocherster, N.Y., and David N. Zacks, MD, PhD, Ann Arbor, Mich.
Dr. Kleinman is a part-time associate professor of ophthalmology at the Flaum Eye Institute at the University of Rochester where he specializes in the medical and surgical care of patients with retinal disease. He has spent more than 10 years working in retinal pharmaceutical development and currently serves as the chief medical officer at ONL Therapeutics Inc.


ONL Therapeutics Announces Management Team Additions – ONL Therapeutics

The company has appointed David Kleinman, M.D. as chief medical officer and Linda Johnson as senior vice president of operations, bringing significant industry experience to ONL in the area of ocular drug development.
Dr. Kleinman is also a retina specialist and has spent over ten years in venture creation and ophthalmic drug and device development. He currently serves as part-time associate professor of ophthalmology on the retina service at the Flaum Eye Institute at the University of Rochester. Previously, Dr. Kleinman helped found MacuSight, a venture capital backed retinal drug development company, where he served as consulting medical director. In his role with MacuSight David assisted in guiding the company through Series A financing, pre-clinical studies, investigational new drug (IND) submission, and Phase I/II clinical development. David has extensive experience consulting for both small and large ophthalmic companies in clinical trial design and execution, regulatory interaction, drug safety monitoring, and the evaluation and advancement of novel ophthalmic technology.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory